Header Logo

Connection

PEDRO PIEDRA to Antibodies, Neutralizing

Back to Details
This is a "connection" page, showing publications PEDRO PIEDRA has written about Antibodies, Neutralizing.
PEDRO PIEDRA
Connection Strength
2.503
Antibodies, Neutralizing
  1. Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults. Front Immunol. 2019; 10:706.
    View in: PubMed
    Score: 0.477
  2. Respiratory Syncytial Virus (RSV): Neutralizing Antibody, a Correlate of Immune Protection. Methods Mol Biol. 2016; 1442:77-91.
    View in: PubMed
    Score: 0.381
  3. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis. 2012 Apr; 54(7):905-12.
    View in: PubMed
    Score: 0.289
  4. The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent. J Virol. 2023 05 31; 97(5):e0025423.
    View in: PubMed
    Score: 0.158
  5. Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein. Vaccine. 2022 01 24; 40(3):536-543.
    View in: PubMed
    Score: 0.144
  6. Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients. Viruses. 2021 05 26; 13(6).
    View in: PubMed
    Score: 0.138
  7. Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine. Expert Rev Vaccines. 2021 04; 20(4):351-364.
    View in: PubMed
    Score: 0.138
  8. A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas. Vaccine. 2021 02 22; 39(8):1248-1256.
    View in: PubMed
    Score: 0.135
  9. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016 01; 60(1):6-13.
    View in: PubMed
    Score: 0.094
  10. Infection with novel respiratory syncytial virus genotype Ontario (ON1) in adult hematopoietic cell transplant recipients, Texas, 2011-2013. J Infect Dis. 2015 Feb 15; 211(4):582-9.
    View in: PubMed
    Score: 0.087
  11. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs. 2013 Mar-Apr; 5(2):263-9.
    View in: PubMed
    Score: 0.078
  12. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013 Jan 07; 31(3):524-32.
    View in: PubMed
    Score: 0.077
  13. Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection. Vaccine. 2021 07 05; 39(30):4063-4071.
    View in: PubMed
    Score: 0.035
  14. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021 01 14; 12(1):372.
    View in: PubMed
    Score: 0.034
  15. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020 11 25; 38(50):7892-7896.
    View in: PubMed
    Score: 0.033
  16. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 12 10; 383(24):2320-2332.
    View in: PubMed
    Score: 0.033
  17. Antigenic Fingerprinting of Respiratory Syncytial Virus (RSV)-A-Infected Hematopoietic Cell Transplant Recipients Reveals Importance of Mucosal Anti-RSV G Antibodies in Control of RSV Infection in Humans. J Infect Dis. 2020 02 03; 221(4):636-646.
    View in: PubMed
    Score: 0.032
  18. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine. 2018 12 18; 36(52):8069-8078.
    View in: PubMed
    Score: 0.029
  19. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. 2017 06 27; 35(30):3749-3759.
    View in: PubMed
    Score: 0.026
  20. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol. 2016 08 15; 90(16):7508-7518.
    View in: PubMed
    Score: 0.025
  21. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22; 111(16):5992-7.
    View in: PubMed
    Score: 0.021
  22. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. J Virol. 2014 May; 88(9):5100-8.
    View in: PubMed
    Score: 0.021
  23. Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised). BMC Res Notes. 2013 May 03; 6:177.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.